Nature Rev Drug DiscOvjeren akaunt

@NatRevDrugDisc

Editorial team of Nature Reviews Drug Discovery.

London
nature.com/nrd
Vrijeme pridruživanja: travanj 2009.
818 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @NatRevDrugDisc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NatRevDrugDisc

  1. prije 1 sat

    Our February issue includes a comprehensive review on technology platforms that can be used to develop drugs for rare diseases and a comment article explaining why coordinated efforts to better define rare diseases are needed

    4 proslijeđena tweeta 10 korisnika označava da im se sviđa
    Poništi
  2. 4. velj

    Our February issue is published today - featuring articles on rare diseases, FDA drug approvals in 2019, mRNA processing as an anticancer target, predictive models for drug-induced liver injury and more!

    5 proslijeđenih tweetova 9 korisnika označava da im se sviđa
    Poništi
  3. proslijedio/la je Tweet
    3. velj

    Came across this beauty on the development of allo CAR-T cells in . Highlights include different sources of T cells (IPSCs), gene editing strategies to minimize GVHD, perspective on solid tumors and challenges that still remain.

    4 proslijeđena tweeta 10 korisnika označava da im se sviđa
    Poništi
  4. 3. velj

    Find out about opportunities for drug discovery targeting adhesion G protein-coupled receptors in this recent perspective

    6 proslijeđenih tweetova 12 korisnika označava da im se sviđa
    Poništi
  5. 31. sij

    From the January issue - a news article discussing the pipeline of immune agonist antibodies as the first one enters phase III trials And for more on agonist antibodies in cancer , here's a recent review

    5 proslijeđenih tweetova 9 korisnika označava da im se sviđa
    Poništi
  6. 30. sij

    Sandra Horning, outgoing Chief Medical Officer at Roche, discusses the company’s approach to cancer immunotherapy, haematology, real-world evidence and more in our interview published today

    1 proslijeđeni tweet 4 korisnika označavaju da im se sviđa
    Poništi
  7. 29. sij

    Matthew Disney is talking about how to approach RNA as a target for small-molecule probes and drugs at - here's a perspective with more on this topic

    1 reply 10 proslijeđenih tweetova 34 korisnika označavaju da im se sviđa
    Poništi
  8. 29. sij

    Michael Kossenjans from AstraZeneca is talking about taking automated chemistry in drug discovery from idea to reality at - for readers interested in automating drug discovery, here's a recent perspective

    11 proslijeđenih tweetova 22 korisnika označavaju da im se sviđa
    Poništi
  9. proslijedio/la je Tweet
    28. sij

    A call for better microbiome animal-model papers - and an indictment of the ones we have:

    1 reply 8 proslijeđenih tweetova 17 korisnika označava da im se sviđa
    Poništi
  10. 28. sij

    Find out about the pipeline and market for tumour-agnostic therapies in this article published today by and colleagues

    3 proslijeđena tweeta 17 korisnika označava da im se sviđa
    Poništi
  11. 27. sij

    Jackie Hunter, CEO of BenevolentBio, is presenting on applications of in pharmaceutical R&D at the meeting today - here's a review of the field

    8 proslijeđenih tweetova 15 korisnika označava da im se sviđa
    Poništi
  12. proslijedio/la je Tweet
    25. sij

    A great review on therapeutic interventions targeting neutrophils

    Neutrophils as emerging therapeutic targets in infection, pulmonary diseases, cardiovascular diseases, inflammatory disorders and cancer - a new review published today
    6 proslijeđenih tweetova 22 korisnika označavaju da im se sviđa
    Poništi
  13. 24. sij

    From the January issue - a review on synthetic lethality as an engine for cancer drug target discovery

    8 proslijeđenih tweetova 26 korisnika označava da im se sviđa
    Poništi
  14. 23. sij

    For more on mRNA vaccines that could be useful in responding to pandemic threats such as the latest coronavirus, here's a review

    1 proslijeđeni tweet 14 korisnika označava da im se sviđa
    Poništi
  15. proslijedio/la je Tweet
    23. sij

    New players are jumping into an old vaccine game as pandemic panic spreads fast — putting their tech to the test

    1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
    Poništi
  16. 23. sij

    From the January issue - a review on targeting metabolic dysregulation in fibrosis to treat diseases such as NASH and heart failure

    6 proslijeđenih tweetova 16 korisnika označava da im se sviđa
    Poništi
  17. proslijedio/la je Tweet
    23. sij

    Another look at 2019 M&A from A total of $238B was spent in 2019 across 310 transactions. -related deals represented the most by volume, contributing to 28% of the total. Article:

    1 reply 3 proslijeđena tweeta 10 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  18. 23. sij

    New paper shows selective BD2 bromodomain targeting improves the therapeutic window of BET inhibitors in cancer - read our research highlight here For more on bromodomain inhibitors, here's a review

    6 proslijeđenih tweetova 14 korisnika označava da im se sviđa
    Poništi
  19. 22. sij

    This Comment article published today proposes a platform trial approach to improve the effectiveness of drug development for autism spectrum disorders For more on platform trials, here's a recent Perspective

    1 proslijeđeni tweet
    Poništi
  20. 22. sij

    Neutrophils as emerging therapeutic targets in infection, pulmonary diseases, cardiovascular diseases, inflammatory disorders and cancer - a new review published today

    10 proslijeđenih tweetova 19 korisnika označava da im se sviđa
    Poništi

@NatRevDrugDisc još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·